Na mbido ọrịa a, Foregene lebara ya anya nke ọma, wee hazie nyocha sayensị ozugbo itinye ego na R&D nke ngwa nchọpụta nucleic acid coronavirus ọhụrụ.Dabere na afọ nke oke mmiri ozuzo na ahụmịhe, ndị otu ahụ jiri teknụzụ patent PCR Direct mepụta ngwa ngwa nchọpụta coronavirus (SARS-CoV-2).

Ngwa a adịghị mkpa wepụ nucleic acid site na ihe nlele ahụ, ma nwee ike ịme nchọpụta PCR nke oge fluorescent quantitative mgbe nhazi ntọhapụ nucleic acid dị mfe, nke na-eme ka usoro nhazi usoro nhazi dị mfe, na-ezere ọnwụ nke nucleic acid nke ihe nlele ahụ, ma nweta nsonaazụ ule n'ime 1 hour, karịsịa kwesịrị ekwesị maka mkpa nyocha ngwa ngwa buru ibu.

Site na mgbasa nke ọrịa zuru ụwa ọnụ, dị ka onye so na ụlọ ọrụ IVD nke China, Foregene na-arụkwa ọrụ dị mkpa nke mgbochi ọrịa zuru ụwa ọnụ.Ngwa ahụ nwetara asambodo EU CE na njedebe nke March.N'etiti Eprel, Foregene yana BIOWALKER PTE LTD, Singapore, gafere ndebanye aha Health Sciences Authority (HSA) nke Singapore (Health Sciences Authority, HSA), nke pụtakwara naForegene nwere ike inye aka na mba ofesi ndị ọzọ chọrọ ihe mgbochi nje.

N'ọdịnihu, Foregene ga-akwado àgwà sayensị siri ike ma gaa n'ihu na-enye ngwaahịa na ọrụ arụmọrụ dị elu yana àgwà a pụrụ ịdabere na ya maka nnukwu ahịa abụọ nke nyocha sayensị na nchọpụta.